Example: Heart Attack

Search clinical trials for: Epirubicin

Total 487 results

NCT04498793

Not yet recruiting

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Conditions: HER2-negative Breast Cancer
NCT04490694

Not yet recruiting

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma
NCT04490993

Active, not recruiting

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Conditions: Non-muscle Invasive Bladder Cancer
NCT04474951

Recruiting

Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies

Conditions: Breast Cancer; Gynecologic Cancer
NCT04437160

Recruiting

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Conditions: Triple Negative Breast Cancer
NCT04433156

Recruiting

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Conditions: Marginal Zone Lymphoma
NCT04418154

Recruiting

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Conditions: Triple Negative Breast Cancer
NCT04398914

Recruiting

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Conditions: Breast Cancer Invasive
NCT04335669

Recruiting

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Conditions: Breast Cancer; Triple Negative Breast Neoplasms
NCT04301739

Not yet recruiting

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Conditions: Triple Negative Breast Cancer
NCT04296175

Recruiting

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

Conditions: Triple-negative Breast Cancer
NCT04290793

Not yet recruiting

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Conditions: Breast Cancer
NCT04273100

Recruiting

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC

Conditions: Hepatocellular Carcinoma Non-resectable
NCT04255056

Not yet recruiting

Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab

Conditions: Breast Cancer
NCT04224922

Completed

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Conditions: Breast Cancer
NCT04220944

Recruiting

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Conditions: Hepatic Carcinoma
NCT04214626

Recruiting

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Conditions: Diffuse Large B Cell Lymphoma
NCT04213898

Not yet recruiting

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Conditions: Triple-negative Breast Cancer
NCT04193059

Recruiting

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Conditions: Breast Cancer
NCT04172259

Recruiting

ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC

Conditions: Breast Cancer; Neoadjuvant Chemotherapy
NCT04152057

Recruiting

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Conditions: Breast Cancer; HER2 Positive; Combination Chemotherapy
NCT04152577

Recruiting

R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

Conditions: Lymphoma, B-Cell
NCT04137640

Not yet recruiting

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Conditions: Breast Cancer
NCT04138719

Recruiting

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Conditions: Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxel
NCT04136782

Not yet recruiting

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Conditions: Breast Cancer
NCT04134247

Not yet recruiting

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Conditions: Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT04127019

Completed

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Conditions: Primary Breast Cancer
NCT04103398

Not yet recruiting

TACE Plus Sorafenib Versus TACE Alone for Recurrent Unresectable Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma; Sorafenib; Transarterial Chemoembolization
NCT04094896

Recruiting

TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Conditions: HER2-Positive Breast Cancer
NCT04066790

Terminated

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Conditions: Breast Cancer
NCT04067037

Recruiting

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT04067102

Recruiting

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Conditions: Triple Negative Breast Cancer
NCT04061772

Recruiting

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Conditions: Peripheral T Cell Lymphoma
NCT04059003

Recruiting

CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

Conditions: Breast Neoplasms
NCT04036994

Not yet recruiting

PBMT for the Management of CIA ( HAIRLASER )

Conditions: Breast Cancer; Chemotherapy-induced Alopecia; Alopecia
NCT04031703

Completed

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Conditions: Breast Cancer
NCT03983096

Completed

Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.

Conditions: Breast Cancer
NCT03983538

Active, not recruiting

Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer

Conditions: Breast Cancer
NCT03925233

Enrolling by invitation

Breast Cancer Treatment Based on Organ-like Culture

Conditions: Breast Cancer Organoids
NCT03894007

Recruiting

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Conditions: Early-stage Breast Cancer; HER2-positive Breast Cancer
NCT03892330

Not yet recruiting

Combination Therapy of Anthracyclines for Children With Nephroblastoma

Conditions: 0.5-14 Year Old Children With Nephroblastoma
NCT03888677

Completed

Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer

Conditions: Breast Cancer
NCT03879577

Active, not recruiting

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Conditions: Breast Cancer; Breast Cancer Female; HER2-positive Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III
NCT03876886

Recruiting

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

Conditions: Triple Negative Breast Cancer
NCT03839550

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Conditions: Hepatocellular Carcinoma
NCT03815474

Recruiting

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

Conditions: Sarcoma, Soft Tissue
NCT03799679

Recruiting

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Conditions: Triple Negative Breast Cancer
NCT03785704

Recruiting

Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer

Conditions: Breast Neoplasms; Cardiac Event; Chemotherapeutic Toxicity
NCT03756090

Not yet recruiting

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer

Conditions: Breast Cancer; Breast Diseases; Breast Neoplasms
NCT03755115

Not yet recruiting

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Conditions: Small Cell Lung Cancer Extensive Stage

Search clinical trials for: Epirubicin

Recent CRA jobs

Safety Admin

Research Scientist - LCMS - Method Development

Data Analyst II – Real World Evidence

Clinical Team Manager (Local Study Manager) FSP

Senior Logistics Coordinator / Senior Sample Coordinator - Sample Management , LIMS , GMP

Associate HR Director - Business Partner

Associate Scientist - Part-time Weekends

QC Reviewer / Senior QC Reviewer - LIMS , GMP

Site Alliance Manager

Principal Clinical Database Programmer